Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR-Mutant Lung Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT03410043
What this trial is testing

Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study

Who this might be right for
Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell CarcinomaStage IIIB Lung Cancer AJCC v8+3 more
M.D. Anderson Cancer Center 173
Testing effectiveness (Phase 2)Active Not RecruitingNCT03381274
What this trial is testing

Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study

Who this might be right for
Carcinoma, Non-Small-Cell Lung
MedImmune LLC 43
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07802834
What this trial is testing

Adjuvant ctDNA-Adapted Treatment With Zipalertinib in Early-Stage Atypical EGFR-Mutant NSCLC

Who this might be right for
EGFRLung Cancer (NSCLC)Non Small Cell Lung Cancer
Stanford University 42
Testing effectiveness (Phase 2)UnknownNCT05498389
What this trial is testing

EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer

Who this might be right for
Metastatic Lung Non-Small Cell CarcinomaAdvanced Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8+6 more
Shanghai EpimAb Biotherapeutics Co., Ltd. 115
Testing effectiveness (Phase 2)Study completedNCT05017025
What this trial is testing

Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer

Who this might be right for
Advanced Lung Non-Squamous Non-Small Cell CarcinomaMetastatic Lung Non-Squamous Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8+6 more
M.D. Anderson Cancer Center 32
Early research (Phase 1)Ended earlyNCT01219543
What this trial is testing

A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the Expansion Phase.

Who this might be right for
Solid TumourAdvanced Solid MalignanciesChild-Pugh A to B7 Advanced Hepatocellular Carcinoma+3 more
AstraZeneca 47
Testing effectiveness (Phase 2)Active Not RecruitingNCT03831932
What this trial is testing

Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer

Who this might be right for
Advanced Lung Non-Small Cell CarcinomaMetastatic Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8
National Cancer Institute (NCI) 22
Not applicableLooking for participantsNCT07348965
What this trial is testing

Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)Leptomeningeal MetastasisFurmonertinib+1 more
Guangzhou University of Traditional Chinese Medicine 42
Testing effectiveness (Phase 2)Looking for participantsNCT06924398
What this trial is testing

Postoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC（ARMOR2501）

Who this might be right for
Lung Cancer (NSCLC)
Sun Yat-sen University 32
Testing effectiveness (Phase 2)Study completedNCT03076164
What this trial is testing

A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib

Who this might be right for
Lung AdenocarcinomaLung CancerLung Cancer Metastatic+3 more
Memorial Sloan Kettering Cancer Center 24
Testing effectiveness (Phase 2)Looking for participantsNCT07323056
What this trial is testing

Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer

Who this might be right for
EGFR-mutant Non-small Cell Lung CancerPotentially Resectable
Shanghai Pulmonary Hospital, Shanghai, China 36
Early research (Phase 1)Looking for participantsNCT04780568
What this trial is testing

Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer

Who this might be right for
Metastatic Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8+1 more
Ohio State University Comprehensive Cancer Center 25
Large-scale testing (Phase 3)Not Yet RecruitingNCT07680790
What this trial is testing

Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

Who this might be right for
Non-Small Cell Lung Cancer
Bristol-Myers Squibb 850
Not applicableUnknownNCT02618590
What this trial is testing

A Retrospective Study About Treatment Strategy After First/Second Line EGFR-TKI Failure

Who this might be right for
Non-Small Cell Lung Cancer
Sun Yat-sen University 800
Testing effectiveness (Phase 2)Looking for participantsNCT07518160
What this trial is testing

JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study

Who this might be right for
Locally Advanced, Metastatic, or Recurrent Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations
Shanghai Junshi Bioscience Co., Ltd. 35
Not applicableWithdrawnNCT03872440
What this trial is testing

PDX Models From EGFR Mutant Tumors

Who this might be right for
Non Small Cell Lung Cancer
Addario Lung Cancer Medical Institute
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06537297
What this trial is testing

Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases

Who this might be right for
Non-small Cell Lung Cancer
Hunan Province Tumor Hospital 30
Early research (Phase 1)UnknownNCT04772235
What this trial is testing

Phase I Study of Repotrectinib and Osimertinib in NSCLC Patients

Who this might be right for
Nsclc
Instituto Oncológico Dr Rosell 32
Testing effectiveness (Phase 2)Active Not RecruitingNCT01553942
What this trial is testing

Afatinib With CT and RT for EGFR-Mutant NSCLC

Who this might be right for
Lung Cancer
Massachusetts General Hospital 19
Very early researchNot Yet RecruitingNCT06557096
What this trial is testing

CSF CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therapy in EGFR-Mutant Advanced NSCLC

Who this might be right for
Non Small Cell Lung CancerCirculating Tumor CellEGF-R Positive Non-Small Cell Lung Cancer
Second Affiliated Hospital of Nanchang University 100
Next Page